PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34418168-4	2021	NordCML007 was initiated to study the efficacy and safety of low dose pegylated IFN-alpha (PegIFN-alpha) in combination with dasatinib (DAS) in CML-CP.	pegifn-alpha	91-103	interferon alpha 1	Homo sapiens	80-89
32630479-0	2020	Changes in miR-122 and Cholesterol Expression in Chronic Hepatitis C Patients after PegIFN-Alpha/Ribavirin Treatment.	pegifn-alpha	84-96	microRNA 122	Homo sapiens	11-18
35610746-0	2022	STAT4 genetic polymorphism significantly affected HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients receiving Peginterferon-alpha therapy: A prospective cohort study in China Running title: STAT4 variation affecting response to PegIFN-alpha therapy.	pegifn-alpha	246-258	signal transducer and activator of transcription 4	Homo sapiens	0-5
32663850-7	2021	PegIFN-alpha treatment upregulated exosomal hsa-miR-193a-5p, hsa-miR-25-5p, and hsa-miR-574-5p that could partially inhibit HBV replication and transcription.	pegifn-alpha	0-12	microRNA 25	Homo sapiens	61-71
32663850-7	2021	PegIFN-alpha treatment upregulated exosomal hsa-miR-193a-5p, hsa-miR-25-5p, and hsa-miR-574-5p that could partially inhibit HBV replication and transcription.	pegifn-alpha	0-12	microRNA 574	Homo sapiens	80-91
32294532-7	2020	In addition, pegIFN-alpha/ribavirin therapy induced C19orf66 expression in CHC patients.	pegifn-alpha	13-25	shiftless antiviral inhibitor of ribosomal frameshifting	Homo sapiens	52-60
32630479-5	2020	The purpose of this study was to investigate the impact of peginterferon alpha (pegIFN-alpha) and ribavirin treatments on the expression of miR-122 and the cholesterol level in the peripheral blood mononuclear cells (PBMCs) of CHC patients.	pegifn-alpha	80-92	microRNA 122	Homo sapiens	140-147
32630479-8	2020	Consequently, it seems that the decrease of miR-122 expression in the PBMCs of CHC patients is one of the antiviral effects connected with the pegIFN-alpha/ribavirin treatments.	pegifn-alpha	143-155	microRNA 122	Homo sapiens	44-51
31593639-2	2019	Herein, we reviewed the pharmacokinetics and pharmacodynamics of pegylated IFN-alpha (PegIFN-alpha) for the treatment of HBV.	pegifn-alpha	86-98	interferon alpha 1	Homo sapiens	75-84
31593639-5	2019	PegIFN-alpha did not affect the metabolism of the cytochrome P450 (CYP) isozymes, except inhibition of CYP1A2.	pegifn-alpha	0-12	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	103-109
26836972-2	2016	The aim was to analyze whether IL15 rs10833 is associated with liver disease severity and response to pegylated-interferon-alpha plus ribavirin (pegIFN-alpha/RBV) therapy in human immunodeficiency virus (HIV)-/HCV-co-infected patients.	pegifn-alpha	145-157	interleukin 15	Homo sapiens	31-35
29271328-8	2018	This study illustrated that the carriage of IL28B rs12980275 AA had a positive effect on treatment response to pegIFN-alpha/RBV among Chinese CHC patients.	pegifn-alpha	111-123	interferon lambda 3	Homo sapiens	44-49
29039469-10	2017	The present study illustrated that the carriage of LMP7 rs2071543-AA and TAP2 rs1800454-AA had a negative effect on treatment response to pegIFN-alpha/RBV among genotype 1 patient with CHC in a Chinese Han population.	pegifn-alpha	138-150	proteasome 20S subunit beta 8	Homo sapiens	51-55
29039469-10	2017	The present study illustrated that the carriage of LMP7 rs2071543-AA and TAP2 rs1800454-AA had a negative effect on treatment response to pegIFN-alpha/RBV among genotype 1 patient with CHC in a Chinese Han population.	pegifn-alpha	138-150	transporter 2, ATP binding cassette subfamily B member	Homo sapiens	73-77
26836972-11	2016	CONCLUSIONS: The presence of IL15 rs10833 AA genotype in HIV-/HCV-co-infected patients was associated with advanced liver fibrosis, inflammation-related biomarkers and increased rates of SVR to pegIFN-alpha/RBV therapy.	pegifn-alpha	194-206	interleukin 15	Homo sapiens	29-33
21111740-9	2011	CONCLUSIONS: IL28B genotype and hepatic expression of ISGs are independent predictors of response to treatment with pegIFN-alpha and ribavirin in patients with chronic hepatitis C. The most accurate prediction of response was obtained with a 4-gene classifier comprising IFI27, ISG15, RSAD2, and HTATIP2.	pegifn-alpha	116-128	interferon lambda 3	Homo sapiens	13-18
26499461-3	2016	The aim of this study was to determine whether CXCL12 polymorphisms are related so as to achieve sustained virological response (SVR) after HCV therapy with pegylated-interferon-alpha/ribavirin (pegIFN-alpha/ribavirin) in HIV/HCV-coinfected patients.	pegifn-alpha	195-207	C-X-C motif chemokine ligand 12	Homo sapiens	47-53
21480323-11	2011	The sustained efficacy of IFN-beta and IFN-lambda could be an important advantage for the treatment patients who are nonresponders to pegIFN-alpha, through a preactivated endogenous IFN system.	pegifn-alpha	134-146	interferon beta 1	Homo sapiens	26-34
21480323-11	2011	The sustained efficacy of IFN-beta and IFN-lambda could be an important advantage for the treatment patients who are nonresponders to pegIFN-alpha, through a preactivated endogenous IFN system.	pegifn-alpha	134-146	interferon alpha 1	Homo sapiens	26-29
21480323-11	2011	The sustained efficacy of IFN-beta and IFN-lambda could be an important advantage for the treatment patients who are nonresponders to pegIFN-alpha, through a preactivated endogenous IFN system.	pegifn-alpha	134-146	interferon alpha 1	Homo sapiens	39-42
21111740-9	2011	CONCLUSIONS: IL28B genotype and hepatic expression of ISGs are independent predictors of response to treatment with pegIFN-alpha and ribavirin in patients with chronic hepatitis C. The most accurate prediction of response was obtained with a 4-gene classifier comprising IFI27, ISG15, RSAD2, and HTATIP2.	pegifn-alpha	116-128	interferon alpha inducible protein 27	Homo sapiens	271-276
21111740-9	2011	CONCLUSIONS: IL28B genotype and hepatic expression of ISGs are independent predictors of response to treatment with pegIFN-alpha and ribavirin in patients with chronic hepatitis C. The most accurate prediction of response was obtained with a 4-gene classifier comprising IFI27, ISG15, RSAD2, and HTATIP2.	pegifn-alpha	116-128	ISG15 ubiquitin like modifier	Homo sapiens	278-283
21111740-9	2011	CONCLUSIONS: IL28B genotype and hepatic expression of ISGs are independent predictors of response to treatment with pegIFN-alpha and ribavirin in patients with chronic hepatitis C. The most accurate prediction of response was obtained with a 4-gene classifier comprising IFI27, ISG15, RSAD2, and HTATIP2.	pegifn-alpha	116-128	radical S-adenosyl methionine domain containing 2	Homo sapiens	285-290
21111740-9	2011	CONCLUSIONS: IL28B genotype and hepatic expression of ISGs are independent predictors of response to treatment with pegIFN-alpha and ribavirin in patients with chronic hepatitis C. The most accurate prediction of response was obtained with a 4-gene classifier comprising IFI27, ISG15, RSAD2, and HTATIP2.	pegifn-alpha	116-128	HIV-1 Tat interactive protein 2	Homo sapiens	296-303
17034579-13	2006	In conclusion, a significant reduction of CD4(+) and CD8(+) T cells, and of their CD45RA(+) and CD45RO(+) subpopulations, in HIV/HCV co-infected patients treated with pegIFN-alpha was observed.	pegifn-alpha	167-179	CD4 molecule	Homo sapiens	42-45
21048934-1	2010	Recent genome-wide association studies report that the SNP rs8099917, located 8.9 kb upstream of the start codon of IL28B, is associated with both disease chronicity and therapeutic response to pegIFN-alpha and RBV in patients infected with genotype 1 HCV.	pegifn-alpha	194-206	interferon lambda 3	Homo sapiens	116-121
17034579-13	2006	In conclusion, a significant reduction of CD4(+) and CD8(+) T cells, and of their CD45RA(+) and CD45RO(+) subpopulations, in HIV/HCV co-infected patients treated with pegIFN-alpha was observed.	pegifn-alpha	167-179	CD8a molecule	Homo sapiens	53-56